0.98
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Bio-heart Biological Technology Co
Its shares trade on HKEX under the ticker 2185.HK. It has been listed since 23 December 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥51.0m and a net loss of CN¥79.5m. At that date it held total assets of CN¥969.8m and shareholders' equity of CN¥506.6m.
Shanghai Bio-Heart Biological Technology Co., Ltd. engages in the research and development of interventional cardiovascular device therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-12-23. The firm's main businesses are the development and production of interventional cardiovascular devices. The firm's main products include fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The firm's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 23 Dec 2021
- Employees
- 58
- Website
- bio-heart.com ↗
Leadership
Pay as last reported
- Mr. Wang LiExecutive Chairman of the Board, General Manager, since 2014CN¥61.4m
- Mr. Yunqing WangChief Financial Officer, Executive Director, Board Secretary, Joint Company Secretary, since 2020CN¥8.9m
- Ms. Peili WangExecutive Director, since 2014
- Mr. Tao CaiHead - Technology, since 2020CN¥4.7m
- Dr. Bradley HubbardChief Medical Officer
- Mr. Chenzhao ZhangHead - Technology
- Ms. Siu Ying KwokJoint Company Secretary
- Mr. Yiqing ChenIndependent Non-Executive Director
- Mr. Yifei JiangIndependent Non-Executive Director
- Mr. Xubo LuNon-Executive Independent DirectorCN¥33,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Bio-Heart Biological Technology Co Ltd develops interventional cardiovascular device therapies.
- The firm employs 58 full-time staff members in its operations.
- Main products include fully bioresorbable scaffolds and renal denervation devices.
Weaknesses
- The company has a small workforce of only 58 employees.
- Shanghai Bio-Heart Biological Technology Co Ltd is headquartered in Shanghai.
- The firm went public on 23 December 2021 via an IPO.
Opportunities
- Products treat coronary artery disease and peripheral artery disease needs.
- Renal denervation devices address medical needs for hypertension treatment.
- Development of bioresorbable scaffolds supports interventional cardiovascular therapy advancements.
Threats
- Shanghai Bio-Heart Biological Technology Co Ltd operates in the Health Care sector.
- The company is listed on the market in China.
- Competitors in the interventional cardiovascular device market may increase.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.